|
EP3475424A1
(en)
|
2016-06-22 |
2019-05-01 |
ProQR Therapeutics II B.V. |
Single-stranded rna-editing oligonucleotides
|
|
US10941402B2
(en)
|
2016-09-01 |
2021-03-09 |
Proqr Therapeutics Ii B.V. |
Chemically modified single-stranded RNA-editing oligonucleotides
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
AU2022301997A1
(en)
*
|
2021-06-29 |
2024-01-04 |
Shape Therapeutics Inc. |
Engineered guide rnas and polynucleotides
|
|
EP4441219A2
(en)
*
|
2021-12-01 |
2024-10-09 |
Shape Therapeutics Inc. |
Engineered guide rnas and polynucleotides for rna editing targeting lrrk2
|
|
US20250154504A1
(en)
|
2022-02-14 |
2025-05-15 |
Proqr Therapeutics Ii B.V. |
Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
|
|
EP4555086A1
(en)
|
2022-07-15 |
2025-05-21 |
ProQR Therapeutics II B.V. |
Oligonucleotides for adar-mediated rna editing and use thereof
|
|
WO2024013360A1
(en)
|
2022-07-15 |
2024-01-18 |
Proqr Therapeutics Ii B.V. |
Chemically modified oligonucleotides for adar-mediated rna editing
|
|
JP2025525564A
(ja)
*
|
2022-07-18 |
2025-08-05 |
エフ． ホフマン－ラ ロシュ アーゲー |
オリゴヌクレオチドの編集
|
|
JP2025525583A
(ja)
|
2022-07-19 |
2025-08-05 |
ランパート バイオサイエンス インコーポレイテッド |
非免疫原性環状非ウイルス性ｄｎａベクター
|
|
GB202215614D0
(en)
|
2022-10-21 |
2022-12-07 |
Proqr Therapeutics Ii Bv |
Heteroduplex rna editing oligonucleotide complexes
|
|
AR131145A1
(es)
|
2022-11-24 |
2025-02-19 |
Proqr Therapeutics Ii Bv |
Oligonucleótidos antisentido para el tratamiento de hemocromatosis hfe hereditaria
|
|
GB202218090D0
(en)
|
2022-12-01 |
2023-01-18 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
|
|
CA3276262A1
(en)
|
2022-12-09 |
2024-06-13 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
WO2024137991A2
(en)
*
|
2022-12-23 |
2024-06-27 |
Shape Therapeutics Inc. |
Engineered guide rnas and polynucleotides
|
|
GB202300865D0
(en)
|
2023-01-20 |
2023-03-08 |
Proqr Therapeutics Ii Bv |
Delivery of oligonucleotides
|
|
EP4669753A1
(en)
|
2023-02-20 |
2025-12-31 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
|
|
WO2024206175A1
(en)
|
2023-03-24 |
2024-10-03 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurological disorders
|
|
GB202304363D0
(en)
|
2023-03-24 |
2023-05-10 |
Proqr Therapeutics Ii Bv |
Chemically modified antisense oligonucleotides for use in RNA editing
|
|
AU2024246572A1
(en)
|
2023-03-27 |
2025-10-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of liver disease
|
|
WO2024226860A2
(en)
*
|
2023-04-26 |
2024-10-31 |
Shape Therapeutics Inc. |
Small nuclear rna processing hairpins for small rna payloads
|
|
WO2024256620A1
(en)
|
2023-06-16 |
2024-12-19 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurodegenerative disease
|
|
WO2025015091A1
(en)
*
|
2023-07-11 |
2025-01-16 |
Shape Therapeutics Inc. |
Serpina1-targeting engineered guide rnas and polynucleotides
|
|
WO2025051946A1
(en)
|
2023-09-07 |
2025-03-13 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
WO2025104239A1
(en)
|
2023-11-16 |
2025-05-22 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of classic galactosemia
|
|
WO2025132708A1
(en)
|
2023-12-20 |
2025-06-26 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of huntington's disease
|
|
GB202404661D0
(en)
|
2024-04-02 |
2024-05-15 |
Proqr Therapeutics Ii Bv |
Antisense oligoncleotides for the treatment of liver disease
|
|
WO2025224230A1
(en)
|
2024-04-25 |
2025-10-30 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of fatty liver disease
|
|
WO2026006476A1
(en)
*
|
2024-06-25 |
2026-01-02 |
Shape Therapeutics Inc. |
Abca4 vectors and engineered guide rnas
|
|
GB202410081D0
(en)
|
2024-07-11 |
2024-08-28 |
Proqr Therapeutics Ii Bv |
Antisense oligonucleotides for the treatment of cardiovascular disease
|
|
WO2026022136A1
(en)
|
2024-07-23 |
2026-01-29 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of metabolic disorders
|
|
WO2026060374A2
(en)
|
2024-09-16 |
2026-03-19 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of neurological disorders
|
|
WO2026068781A1
(en)
|
2024-09-30 |
2026-04-02 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for the treatment of liver disease
|